This month we’re profiling just a few of the CROs, sponsors, biotech, and pharma companies that have become some of the newest Zelta users – exploring how the platform and our customer support team have helped them overcome their biggest challenges, the features that are driving the most value, and how Zelta is factoring into their future studies. Today we’re spotlighting success stories from Alira Health, Integrated Therapeutic Solutions, Poseida Therapeutics, and Vogenx.
For Jennifer Tucker, Director of Data Management at Alira Health, building their first study on Zelta was relatively simple compared to other platforms they had tried – easy to navigate, create forms, and walk through testing. This first study was a small one, with an easy design – 36 forms, 180 queries, 4 visits + AE, CM, EOS – and only 32 rules. No ePRO or RTSM required. And it was all built from a template within two weeks. The reusability of that template means they don’t need to recreate activities like roles, subject and page statuses, or query types each time – all of which adds up to major time savings for new study builds.
This is further enhanced by Zelta’s reporting flexibility. Compared to other vendors Alira had used in the past, Zelta offers flexibility in, for example, closely breaking down the SDV by both page and field (whereas other platforms only offer the former), saving even more time that would otherwise have to be spent drilling down into the field level in Excel.
Customer support has also been an essential part of Alira’s Zelta experience. When building her first studies on Zelta, Jennifer cites the responsiveness of the customer support team – frequent calls, emails answered within 10 minutes – as instrumental for answering questions on build details.
Having used Zelta for just one year, Jennifer and the Alira team are looking forward to leveraging the platform capabilities like local labs support and automatically enabled edit checks to help alleviate the time spent creating study rules.
Dimitri Fitsialos, CEO of Integrated Therapeutic Solutions, didn’t found his company to be a CRO, but to integrate their services into small- and medium-sized organizations who either didn’t have these capabilities in-house, or did have them but needed extra support – services like clinical writing, pharmacovigilance, regulatory submissions, medical monitoring, protocol development, clinical monitoring and data management. To that end, Integrated Therapeutic Solutions uses Zelta to help design databases that provide cleaner data outputs.
Having the team that’s performing the data monitoring also be a part of the database build provides a new level of control over the data, helping with everything from build time to monitoring to edit checks. Zelta helps Integrated Therapeutic Solutions build databases for clients that are cleaner, faster, and more efficient, with less time spent on monitoring and data management – and most importantly, produces better data in the end.
Ray Carlburg, Associate Director of Data Management at Poseida Therapeutics, shares how the flexibility of the Zelta platform empowered his team to build studies in-house. This flexibility has given them greater control over resourcing and trial timelines, eliminated communication challenges, and saved significant time and money that would otherwise be spent on expensive, time-consuming vendors.
Don’t take our word for it, though – listen to Ray’s story in his own words.
Vogenx: Seamless self-service
Bill Wilkison, the Chief Science Officer for Vogenx, has been using Zelta as their EDC solution for two studies trialing a new inhibitor of reactive hypoglycemia – a drug that doesn’t yet exist on the market, and whose absence has been filled by patients using off-label solutions and dietary workarounds, that are minimally effective at best or restrict the quality of life for the patient. While the first study was managed with the support of a large CRO, its success made choosing Zelta for the second study an easy decision. This new study also provided Vogenx with their first opportunity to build a study from scratch with Zelta – involving a particularly tricky drug randomization component. The experience was not just a seamless one, but one that instilled confidence that Zelta was capable of delivering the self-service support needed to maintain their study maturation goals – so much so that they intend to repeat this formula with a third study on Zelta in the near future.
